Home / Resources / Videos / AACE 2018 / Richard Bergenstal Part 1, Emerging Automated Insulin Delivery Devices

Richard Bergenstal Part 1, Emerging Automated Insulin Delivery Devices

In part 1 of this Exclusive Interview, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed about emerging automated insulin delivery devices and the impact of CGM use on blood sugar management.

Richard Bergenstal MD, is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet Methodist Hospital in Minneapolis, Minnesota.


Transcript of this video segment: Emerging Automated Insulin Delivery Devices

Freed: This is Steve Freed. We’re here at AACE in Boston 2018. And we have with us a very special guest, Dr. Richard Bergenstal, whom we’ve interviewed before, but things keep changing so fast, it’s always interesting to talk to him. Maybe you can just give us a very short overview of what you do and where you do it.

Bergenstal: Yeah. Thanks, Steve, for having me. I’m an adult endocrinologist and I’m the Director of the International Diabetes Center in Minneapolis. So, it’s a large diabetes center but built within a multispecialty clinic, so we work closely with endocrine but also with primary care and we do clinical trials. And our goal is just try to see the people with diabetes get the best possible care.

Freed: And you’re presenting here and I think the title was “The Evolution of the Management of Intensive Diabetes Management” and the specific topic is emerging automated insulin delivery devices. So, you’ve been involved way back when the DCCT trials (happened).

Bergenstal: Right.

Freed: And now, you’re involved in other type of trials. How has, basically, the new way to manage blood sugars using the CGMs made an impact?

Bergenstal: Yeah, I know. It’s a really good question. And for better or for worse, I have seen the whole history here. So, the first 10, 15 years of my career were the DCCT and proving that good control mattered, and the A1C was king. Now, the last 10, 15 years have been sort of saying, “You know there is more than the A1C.” We actually would do much better in managing patients if we looked at their blood sugars. And now, CGM has allowed us to look at their blood sugars on a continual basis, so that’s been a huge — biggest breakthrough, I think, is moving to say, “Let’s really look at the blood sugars. Let’s look at them all day, all night. Let’s look for patterns and let’s adjust accordingly whether you’re adjusting yourself with diet, exercise, injections, or whether you’re now putting the adjustment into the hands of an algorithm and some mathematics.”

Return to the main page.